In vitro evaluation of folate-modified PLGA nanoparticles containing paclitaxel for ovarian cancer therapy.

Autor: Luiz MT; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Abriata JP; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Raspantini GL; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Tofani LB; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Fumagalli F; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., de Melo SMG; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Emery FDS; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Swiech K; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Marcato PD; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil., Lee R; Division of Pharmaceutics and Pharmaceutical Chemistry, Ohio State University, Columbus, OH, USA., Marchetti JM; School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Avenida do café s/n, 14040-903 Ribeirão Preto, SP, Brazil. Electronic address: jmarchet@usp.br.
Jazyk: angličtina
Zdroj: Materials science & engineering. C, Materials for biological applications [Mater Sci Eng C Mater Biol Appl] 2019 Dec; Vol. 105, pp. 110038. Date of Electronic Publication: 2019 Jul 30.
DOI: 10.1016/j.msec.2019.110038
Abstrakt: Ovarian cancer is the most lethal gynecological cancer of female reproductive system. In order to improve the survival rate, some modifications on nanoparticles surfaces have been investigated to promote active targeting of drugs into tumor microenvironment. The aim of this study was the development and characterization of folate-modified (PN-PCX-FA) and unmodified PLGA nanoparticles (PN-PCX) containing paclitaxel for ovarian cancer treatment. Nanocarriers were produced using nanoprecipitation technique and characterized by mean particle diameter (MPD), polydispersity index (PDI), zeta potential (ZP), encapsulation efficiency (EE), DSC, FTIR, in vitro cytotoxicity and cellular uptake. PN-PCX and PN-PCX-FA showed MPD < 150 nm and PDI < 0.2 with high EE (about 90%). Cytotoxicity assays in SKOV-3 cells demonstrated the ability of both formulations to cause cellular damage. PCX encapsulated in PN-PCX-FA at 1 nM showed higher cytotoxicity than PN-PCX. Folate-modified nanoparticles showed a 3.6-fold higher cellular uptake than unmodified nanoparticles. PN-PCX-FA is a promising system to improve safety and efficacy of ovarian cancer treatment. Further in vivo studies are necessary to prove PN-PCX-FA potential.
(Copyright © 2019 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: